Disease-associated remodeling of glycosaminoglycans (GAGs), particularly at the level of sulfation motifs and domain organization, has been extensively documented in oncology and other pathologies. These observations support the research value of developing precision anti-GAG antibodies for mapping, selectivity analysis, and target evaluation.